Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, discusses the possibility of detecting and mitigating adverse events caused by CAR-T therapy including cytokine release syndrome (CRS) and neurotoxicity remotely using medical-grade devices to reduce the time that patients spend in the hospital. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.